We demonstrated that an ascending-ramp biphasic shock has a significantly lower defibrillation threshold and causes release of less than half as much troponin I as a truncated exponential biphasic shock at almost the same energy and at a higher peak voltage than the truncated exponential biphasic shock. This result indicates that the shape of the shock waveform, in addition to the peak voltage and energy of the waveform, affects cardiac damage caused by a shock. The results of this study suggest that, in addition to optimizing the shock waveform to decrease the defibrillation threshold, the shock waveform should be optimized to decrease the damage caused by defibrillation. Therefore, it is theoretically possible that the waveform with the lowest defibrillation threshold may not necessarily cause the least damage. Serendipitously, an ascending-ramp first-phase biphasic waveform has both a lower defibrillation threshold energy and a shape that causes less damage than the truncated exponential biphasic waveform. Further investigation is needed to determine whether an ascending ramp biphasic waveform will cause less shock damage to human hearts. See p 1328.
Improvement in Coronary Blood Flow Velocity With Acute Biventricular Pacing Is Predominantly Due to an Increase in a Diastolic Backward-Travelling Decompression (Suction) Wave
Biventricular pacing is known to improve cardiac contractility. This study shows that, equally, it improves cardiac relaxation and the resultant suction effect from the distal circulation that enhances coronary flow velocity. Both ventricular resynchronization and better-timed filling (atrioventricular optimization) have this effect. Pressure and flow velocity changes that occur in the coronary artery may originate proximally (traveling forward from the aorta) or distally (traveling backward from the microcirculation). Wave intensity analysis is a tool used to identify the origins of any changes, even when they are occurring simultaneously. In systole, myocardial contraction creates a forward compression wave but also an opposing backward compression wave. In contrast, in diastole, myocardial relaxation causes a backward decompression (suction) wave that is not opposed by such a matching forward-traveling wave (because the aortic valve closes). The ability of myocardial relaxation to suck blood into the coronary tree appears to be the predominant drive for coronary perfusion, and this drive can be quantified in the form of the backward-traveling decompression wave. Biventricular pacing increases this wave by enhancing myocardial relaxation, as observed in this study. Increases in ventricular pressure responses, brought about by biventricular pacing or optimization of atrioventricular delay, correspond with increases in coronary flow velocity. See p 1334.
Missed Opportunities: Despite Improvement in Use of Cardioprotective Medications Among Patients With Lower-Extremity Peripheral Artery Disease, Underuse Remains
One of the main goals for treatment of peripheral artery disease (PAD) is risk factor modification and secondary prevention of vascular events by initiating cardioprotective pharmacotherapies. Studies investigating temporal trends and longitudinal use of cardioprotective agents after incident diagnosis of PAD have been limited. With the use of Danish nationwide administrative registries, which capture medication adherence, we demonstrate a significant temporal improvement from 2000 to 2007 in the use of any antiplatelet and statin therapy after incident diagnosis of PAD. However, the use of these medications is modest, such that by 18 months after incident diagnosis, nearly half of patients with PAD alone are not taking any antiplatelet or statin therapy. After adjustment, patients with incident PAD and a history of coronary artery disease are more likely to take cardioprotective medications than patients with incident coronary artery disease alone (no history of PAD). Meanwhile, patients with PAD alone have nearly half the adjusted odds of taking any antiplatelet in comparison with patients with coronary artery disease alone. Although use of cardioprotective medications improved after publication of the American College of Cardiology/ American Heart Association PAD guidelines in 2005, the adjusted odds of any antiplatelet use among patients with PAD alone, compared with patients with coronary artery disease alone, was nearly 35% less, and statin use was 20% less in a more contemporary period (2005) (2006) (2007) . The present analysis underscores the need for systemwide improvements to improve adherence to secondary prevention in this population. See p 1345.
Risk of Elective Major Noncardiac Surgery After Coronary Stent Insertion : A Population-Based Study
For patients with coronary stents, practice guidelines recommend that elective noncardiac surgery be delayed until surgery can be performed safely using antiplatelet therapy with aspirin alone. The suggested delay is 30 to 45 days for bare-metal stents and 1 year for drug-eluting stents. However, these recommendations are largely based on expert opinion and limited data. We therefore conducted a population-based cohort study in Ontario, Canada to describe the risks of major elective noncardiac surgery after stent implantation. After linking populationbased administrative databases to a province-wide coronary stent registry, rates of 30-day major adverse cardiac events (mortality, readmission for acute coronary syndrome, repeat coronary revascularization) were measured among patients who underwent major elective noncardiac surgery from 2003 to 2008 after previous stent implantation. We found that when the interval between stent implantation and surgery was Ͻ45 days, event rates were high for bare-metal (6.7%) and drug-eluting (20.0%) stents. When the interval was 45 to 180 days, the event rate for bare-metal stents was 2.6%, which approached that of nonrevascularized individuals with Revised Cardiac Risk Index scores of 1 to 2. Adjusted analyses suggested this event rate increased further if this interval exceeded 180 days. For drug-eluting stents, the event rate was 1.2% once the interval exceeded 180 days, approaching that of nonrevascularized individuals with Revised Cardiac Risk Index scores of 1. These results suggest that the earliest optimal time for performing major elective noncardiac surgery is 46 to 180 days after bare-metal stent implantation and Ͼ180 days after drug-eluting stent implantation. See p 1355.
Incidence, Causes, and Survival Trends From Cardiovascular-Related Sudden Cardiac Arrest in Children and Young Adults 0 to 35 Years of Age: A 30-Year Review
Limited epidemiological data are available on cardiovascular-related sudden cardiac arrest (SCA) in children and young adults. This study conducted a 30-year review of SCA cases in persons 0 to 35 years of
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Original Research Put Into Perspective for the Practicing Clinician Volume 126 Ⅲ Number 11 Ⅲ September 11, 2012 age treated by emergency medical services in King County, Washington. The study findings indicate that SCA in children and young adults is more common than reported in prior estimates. The study also provides a detailed characterization of the causes affecting different age groups. The most common causes of SCA were congenital abnormalities in individuals 0 to 13 years of age, presumed primary arrhythmia in those 14 to 24 years of age, and coronary artery disease in individuals 25 to 35 years of age. Survival data were also presented, and a favorable survival trend over the last 3 decades lends additional support to contemporary resuscitation protocols for SCA in the young. Although more epidemiological research is needed, these findings may influence the development of more effective screening and targeted strategies for prevention of SCA in children and young adults. See p 1363.
Cyclooxygenase-2-Derived Prostacyclin Regulates Arterial Thrombus Formation by Suppressing Tissue Factor in a Sirtuin-1-Dependent-Manner
Prostanoids, generated by cyclooxygenase (COX)-1 and/or COX-2, exert a variety of pathophysiological activities, including platelet aggregation and leukocyte-endothelial cell adhesion, vasorelaxation, and vasoconstriction, and participate in the inflammatory response. In particular, inappropriate prostanoid production under pathological conditions is implicated in arterial thrombosis. COX-2 inhibitors, recently developed with the aim of selectively controlling the contribution of COX-2-derived prostanoids to a variety of diseases, are currently used to treat inflammatory diseases, pain, and cancer. However, the increased incidence of adverse cardiovascular events observed after long-term administration of COX-2 inhibitors has limited their potential beneficial use. The mechanisms responsible for these toxic effects are still under debate, and it has been proposed that endogenous prostacyclin reduction, consequent to inhibition of COX-2, may play a critical role in these adverse effects. In this study, we examined the involvement of COX-2 inhibition or deletion in arterial thrombosis. We discovered that prostacyclin modulates sirtuin-1expression by prostacyclin receptor and/or peroxisome proliferator-activated receptor-␦ pathways with consequent upregulation of tissue factor. Our data not only support the role of COX-2-derived prostacyclin in controlling arterial thrombus formation but also provide, at least in part, a potential explanation for the adverse cardiovascular effects reported with COX-2 inhibitors. Our data also suggest that strategies aimed at increasing sirtuin-1 activity will help to control tissue factor-mediated thrombogenicity. Thus, our work addresses, in a novel fashion, the current state of the field. See p 1373.
The Cell Motility Modulator Slit2 Is a Potent Inhibitor of Platelet Function
Complications of vascular injury and atherosclerosis are the leading cause of mortality and morbidity in the Western world. In atherosclerosis, infiltrating leukocytes and vascular smooth muscle cells cause progressive vascular narrowing. Platelet-mediated thrombosis ultimately causes complete vessel occlusion, resulting in heart attack or stroke. In animal models and human patients, individually blocking these events, eg, with antiplatelet therapy, is only partially effective. Another therapeutic strategy is to target these multiple cell types globally. Slit proteins act as developmental neuronal repellents, and Slit2, via an interaction with its receptor, Robo-1, impairs inflammatory recruitment of leukocytes and vascular smooth muscle cells. However, thus far, the role of Slit2 in modulating platelet functions has not been explored. We report here the novel finding that human and mouse platelets express Robo-1 on their surface, making platelets potentially Slit2-responsive cells. Using static and shear assays, we demonstrate that Slit2 impaired platelet adhesion and spreading on a variety of physiologically relevant extracellular matrix proteins. Mouse tail bleeding assays and intravital microscopy further demonstrated that Slit2 is a powerful negative regulator of platelet function in vivo, prolonging bleeding time and preventing thrombus formation in mice during arterial injury. Slit2 mediated these effects, in part, by suppressing activation of Akt but not Rac1, Cdc42, extracellular signal-regulated kinase, or p38 mitogen-activated protein kinase. These results, combined with the established ability of Slit2 to block chemotaxis of leukocytes and vascular smooth muscle cells, indicate that Slit2, a naturally occurring protein, has the potential to be broadly effective in preventing and treating atherothrombosis and vascular injury. See p 1385.
